Recent discoveries in genetics and genomics hold great promise for the development of target-defined prevention- and chemotherapeutic-strategies for breast and ovarian cancer. However, a coordinated, multidisciplinary research effort is required to translate these new research discoveries into the next generation of therapeutic strategies. To meet this challenge the Breast and Ovarian Cancer Program aims to 1) define eariy events in breast and ovarian carcinogenesis, 2) translate these advances into targeted therapeutic approaches for the prevention and treatment of breast and ovarian cancer, and 3) test these new therapies in investigator-initiated and multi-institutional clinical trials. The Program includes 29 full and 10 associate members from twelve basic and clinical departments within Duke University. Total funding for program members is $15,171,183, of which $10,468,237 is from peer-reviewed sources. A cancer focus is illustrated by $8,076,169 or 77.1% of funding from the NCI, the American Cancer Society or the Department of Defense. Since its inception, the Program has successfully fostered scientific interabtions between members of the Duke Comprehensive Cancer Institute (DCCI) who have basic, translational, and clinical research interests in breast and ovarian cancer. Within the domain of the Program we developed five subprograms that draw from our translational research strength and ability to translate basic science discoveries to impact the eariy detection and treatment of breast and ovarian cancer: 1) Eariy detection strategies for breast and ovarian cancer;2) Methylation imprinting and epigenetic dysregulation;3) Basic breast and ovarian cancer biology and novel therapeutic targeting;4) Genomics;and 5) Disparities for African American women. The diversity of interest and experimental approaches used by the members of the Breast and Ovarian Program represents an effective environment for fostering cross-fertilization of ideas aimed at understanding breast and ovarian cancer. In addition, the Program supports developmental projects, new faculty awards, and tissue procurement and banking. From 2004-2008, program members published 737 papers in peerreviewed journals that bear directly on breast and/or ovarian cancer (increased 498). Program members are highly collaborative. Of these publications, 46% are the result of inter-programmatic collaborations and 51% due to intra-program collaborations (increased from 6% and 10% respectively in 2003).

Public Health Relevance

Breast arid Ovarian Cancer Program fosters scientific interactions between basic, translational, and clinical scientists to generate novel therapeutic strategies for the prevention, detection, and treatment of breast and ovarian cancer. The multi-disiciplinary collaborations fostered by the program allow investigators to make translational discoveries that could not be made by investigators working in isolation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications